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Abstract
We present a retrospective investigation of the role of genomics in the prediction of central versus 
marginal disease progression patterns for glioblastoma (GBM). Between August 2000 and May 
2010, 41 patients with GBM and gene expression and methylation data available were treated with 
radiotherapy with or without concurrent temozolomide. Location of disease progression was 
categorized as within the high dose (60 Gy) or low dose (46 Gy) volume. Samples were grouped 
into previously described TCGA genomic groupings: Mesenchymal (m), classical (c), proneural 
(pn), and neural (n); and were also classified by MGMT-Methylation status and G-Cimp 
methylation phenotype. Genomic groupings and methylation status were investigated as a possible 
predictor of disease progression in the high dose region, progression in the low dose region, and 
Correspondence to: Jordan A. Holmes, jordan.holmes@unchealth.unc.edu.
Compliance with ethical standards
Conflicts of interest None.
HHS Public Access
Author manuscript
J Neurooncol. Author manuscript; available in PMC 2015 September 27.
Published in final edited form as:













time to progression. Based on TCGA category there was no difference in OS (p = 0.26), 60 Gy 
progression (PN: 71 %, N: 60 %, M: 89 %, C: 83 %, p = 0.19), 46 Gy progression (PN: 57 %, N: 
40 %, M: 61 %, C: 50 %, p = 0.8) or time to progression (PN: 9 months, N:15 months, M: 9 
months, C: 7 months, p = 0.58). MGMT methylation predicted for improved OS (median 25 vs. 13 
months, p = 0.01), improved DFS (median 13 vs. 8 months, p = 0.007) and decreased 60 Gy (p = 
0.003) and 46 Gy (p = 0.006) progression. There was a cohort of MGMT methylated patients with 
late marginal disease progression (4/22 patients, 18 %). TCGA groups demonstrated no difference 
in survival or progression patterns. MGMT methylation predicted for a statistically significant 
decrease in in-field and marginal disease progression. There was a cohort of MGMT methylated 
patients with late marginal progression. Validations of these findings would have implications that 
could affect radiation field size.
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Introduction
Recent advances in the understanding of glioblastoma (GBM) have revealed several 
genomic classes with distinct genetic expression patterns [1]. Clinical correlations 
demonstrated that only one of these classes, the proneural subtype with IDH1 mutation has 
prognostic significance. Much less is known, however, of how genomic subtypes of GBM 
may affect the clinical behavior of these tumors. Recent data has suggested patients with the 
proneural GBM subtype have tumors that are more resectable [2, 3].
Genetic variability can affect a number of clinical variables in patients with GBM including 
responsiveness to therapy, likelihood of pseudoprogression, and the ability to form multiple 
distinct foci. Traditionally, GBM has demonstrated a fairly consistent progression pattern, 
with the great majority of tumors recurring within the highest dose radiation volume, and 
within 2 cm of the index tumor [4]. Since the advent of temozolomide, multiple studies have 
identified a cohort of longer-term survivors that have been found to progress outside the 
highest dose radiation region [5, 6]. The variation from the traditional progression pattern in 
these prolonged survivors suggests that the initial radiotherapy volume may have 
insufficiently treated occult disease in certain patients. If these patients could be identified in 
the upfront setting prior to the radiation treatment planning stage, patients who are destined 
to progress marginally could be treated preemptively with larger treatment volumes to 
potentially better encompass microscopic disease and thereby delay recurrence.
To this end, a single institution retrospective review was performed comparing the genetic 
expression patterns of tumors with different patterns of progression. The goal of the analysis 
was to determine if there were specific genetic profiles including TCGA classification, 
glioma-CpG island methylator phenotype (G-cimp) or hypermethylation of the O6-
methylguanine-DNA-methyltransferase (MGMT) which predicted for delayed treatment 
progression outside of the original high dose radiation volume.
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This study was approved by the Wake Forest School of Medicine Institutional Review 
Board. Our departmental database was searched for patients with a diagnosis of GBM who 
were treated with radiation therapy. Between August 2000 and May 2010, 161 patients with 
GBM were treated with radiotherapy using modern treatment planning techniques. Of this 
group, 51 patients had pre-treatment tissue available in the tumor tissue bank. Of 51 patients 
for which sample existed in the tumor bank, 41 patients had sufficient tissue for analysis. 
Patient characteristics for this population study are summarized in Table 1.
Radiotherapy
Patients were treated at the Wake Forest University Comprehensive Cancer Center using a 
shrinking field technique. The clinical target volume (CTV) margins used for individual 
patients were based upon physician discretion unless the patient was enrolled on a clinical 
trial, in which case the CTV margins were dictated by the trial guidelines. CTV margins for 
this analysis varied from 0.5 to 2.0 cm. Planned treatment volume (PTV) margins were 5 
mm. Intensity modulated radiation therapy was performed on 23 (55 %) patients in this 
cohort, and was generally used in cases where treatment volumes were in close proximity 
with the optic apparatus or brainstem. Radiation dose was 46 Gy prescribed to the pre-boost 
clinical target volume CTV, which included peritumoral edema and CTV margin. The boost 
volume received 60 Gy and included residual enhancing tumor and resection cavity with a 
CTV margin.
Patient follow-up and response assessment
Patients were followed clinically by a multidisciplinary team and with serial MRI. Imaging 
was generally performed in the immediate post-operative setting, 1 month after completion 
of radiation therapy, and then every 2 months for the first six months after completion of 
radiation therapy. Subsequent imaging was performed every 3 months, unless patients 
developed new or progressive symptoms warranting an earlier scan. Electronic medical 
records and imaging review were used to retrospectively determine date of initial 
progression using the response assessment in neuro-oncology (RANO) criteria published by 
Wen et al. [4]. Treatment planning data were fused to MRI at date of progression using the 
Pinnacle treatment planning system (Philips Healthcare, Andover, MA). Location of 
treatment progression was categorized as within the 60 Gy volume, within the 46 Gy volume 
or as distant progression (beyond the 46 Gy volume). Patients were considered to have 
progression in both the 60 and 46 Gy volumes if MRI on the date of progression 
demonstrated new or worsening areas of enhancement that were both enclosed by the 60 Gy 
isodose line, and between the 60 and 46 Gy isodose lines.
Genomic analysis
Fresh-frozen tumor tissues from 51 subjects were available for genomic analyses using 
Affymetrix Human Exon 1.0 ST GeneChips (Affymetrix, Santa Clara, CA) and Infinium 
HumanMethylation (HM) 450 BeadChip from Illumina (Illumina, San Diego, CA). Tissue 
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banking was standardized at our institution in 2008, and tissue obtained prior to that was 
done so more sporadically and was based upon neurosurgeon participation. Tissue banking 
was generally not pursued in patients undergoing stereotactic biopsies because of 
insufficient quantity of tissue. Genomic DNA and total RNA were isolated from these tumor 
samples using a QIAGEN DNA purification kit and TRIzol Reagent from Invitrogen, 
respectively, according to manufacturer’s instructions. The quality of genomic DNA and 
total RNA was evaluated as described previously [7].
We purchased all reagents and carried out transcriptome and genome-wide methylation 
assays following manufacturer’s instructions. Raw data generated from the exon GeneChips 
were first analyzed and evaluated using Affymetrix Expression Console. The data sets 
passed quality controls and were then imported into Partek Genomics Suite 6.6 software and 
Quantile-normalized. Pre-background was adjusted for GC content and for probe sequence. 
Log 2 probe intensities were finally analyzed for association between gene expression and 
clinical outcomes.
These 41 tumors were clustered into clinically relevant gene expression-based molecular 
classifications as previously described by The Cancer Genomic Atlas (TCGA) project 
including the proneural (PN), mesenchymal (M), neural (N), and classical (C) subgroups [8]. 
Hierarchical clustering with average linkage and a panel of 840 genes with high predictive 
values was performed. Raw data generated from the HM450 BeadChip were obtained using 
GenomeStudio software (Illumina). Color balance adjustment, simple scaling normalization 
and data analysis were performed using the Bioconductor lumi package [9]. The b 
(methylation) value was calculated as described previously [10]. DNA methylation profiles 
for these 41 samples were evaluated for methylation of the O6-methylguanine-DNA 
methyltransferase (MGMT) gene, and for G-Cimp methylation phenotype as previously 
described [11, 12].
Statistics
Patterns of progression, time to progression and overall survival were compared based on 
genomic subgroups, and MGMT methylation status. G-CIMP methylation status was 
excluded from analysis due to very small number of patients. Kaplan–Meier analysis was 
used to generate survival curves for time to progression and overall survival. Log rank test 
was used to compare differences between survival curves. The chi square and fisher’s exact 
tests were used to determine differences between genomic groupings and methylation states. 
All statistics were performed using STATA.
Results
Genomic groupings
Genomic subtyping data is summarized in Table 1. Of the 41 patients with gene expression 
data available, 21 (51 %) were found to be of the mesenchymal subgroup. Forty-one patients 
had methylation data available, and of these, 22 (54 %) were MGMT-methylated, and 5 (12 
%) patients were found to have the G-Cimp methylation phenotype.
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Median overall survival for the entire cohort was 17 months. There was no detectable 
difference in overall survival based on TCGA subtype (p = 0.26). Overall survival also did 
not differ by G-Cimp methylation phenotype (p = 0.34). Figure 1 depicts Kaplan-Meier plots 
for overall survival based on MGMT-methylation status, showing that patients with 
methylated MGMT had significantly improved overall survival (median 13 vs. 25 months, p 
= 0.01).
Progression pattern
Of 41 total patients, 36 (88 %) suffered an intracranial progression at a median time of 8 
months. Time to progression did not differ significantly by TCGA grouping (PN: 9 months, 
N:15 months, M: 9 months, C: 7 months, p = 0.58). MGMT-methylated patients were found 
to have significantly longer time to progression (median 13 vs. 8 months, log rank p = 
0.007).
Progression in the 60 Gy volume did not differ significantly by TCGA group (PN: 71 %, N: 
60 %, M: 89 %, C: 83 %, p = 0.19). Progression in the 46 Gy volume also did not differ by 
TCGA group (PN: 57 %, N: 40 %, M: 61 %, C: 50 %, p = 0.8) (Fig. 2). MGMT-methylated 
patients were less likely to have 60 Gy progression (65 vs. 90 %, p = 0.003) and 46 Gy 
progression (47 vs. 63 %, p = 0.006). Overall MGMT-methylated patients were more likely 
to have late progression >12 months, and there was a cohort of MGMT methylated patients 
(n = 4, 18 %) who survived >12 months and had progression involving the 46 Gy volume.
Radiation toxicity and salvage therapy
Use of temozolamide, salvage treatment and progression volume are shown in Table 2. 
Overall only three patients (7 %) developed a ≥grade 3 toxicity as a result of radiation and 
five patients (12 %) developed grade 1–2 fatigue. Salvage therapy was delivered to 18 
patients (43 %) (median number of salvage treatments of zero), and 8 patients (19 %) 
received bevacizumab at any point in their salvage course.
Discussion
The genomic classification of GBM is an evolving field with several distinct genomic 
groupings that appear to have very different biological behaviors, and unique genomic 
alterations [1]; however there is a paucity of data regarding clinical relevance of these 
genomic groupings, specifically as they relate to patterns of progression. Our current study 
presents data that would suggest there is no difference in the patterns of progression based 
on TCGA genomic groupings, or G-Cimp methylation status. This result is somewhat 
surprising given that TCGA groupings and G-Cimp methylation have been showed to affect 
overall survival [13], yet seem to not affect patterns of progression. Whether this lack of 
correlation represents a biological phenomenon or a limitation of our small sample size is 
unknown and will require a larger patient cohort.
The proper radiation treatment volume for patients with GBM has been a controversial topic 
for decades. Whole brain radiotherapy (WBRT) was once the accepted radiation treatment 
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volume because of the local and distant infiltrative behavior of GBM cells [14]. However, 
multiple series have demonstrated that in spite of WBRT, tumors generally recurred within 
2–3 cm of the index tumor[15, 16]. Moreover, biopsy studies have demonstrated consistent 
infiltration of GBM cells into regions of peritumoral edema [17] causing many to argue for 
targeted inclusion of the T2 signal abnormality into the GBM treatment volume. As a result 
of this difference in targeting philosophies, radiation treatment volumes have evolved 
differently between European cooperative groups, which suggested a 2–3 cm margin around 
the enhancing index tumor, and those in the US including the cohort described here, which 
additionally targeted the T2- or FLAIR-hyperintense regions [14]. Recently, studies have 
also demonstrated that treating smaller margins as low as a 5 mm CTV may also be safe [6, 
18].
Perhaps the most intriguing observation of the present study was the cohort of MGMT 
methylated patients who had low dose or out-of-field progression. We found that 5 of 16 
MGMT methylated patients (31 %) who had experienced progression did so in either the 
low dose region or distantly. Patients without MGMT methylation experienced some 
component of progression within the highest dose region in 16 out of 19 patients (85 %). 
There appears to be a group of MGMT methylated patients who respond well to initial 
treatment only to progress in the margin. MGMT is a DNA repair enzyme that when 
methylated becomes transcriptionally down-regulated. When MGMT levels are lower, 
DNA-damaging agents such as temozolomide and radiotherapy become more effective, 
because the tumor cells cannot repair the DNA damage as efficiently. It may be that 
MGMT-methylated tumors, because of their increased sensitivity to treatment, represent a 
population where increased radiation dose to the regions of minimal tumor spread may be 
more relevant because the doses to gross disease are more effective. As such, if the current 
data can be validated in larger cohort this might suggest that MGMT-methylated tumors 
represent a population that may benefits from larger high dose CTV margins. With any 
increase in margin size or dose there is likely to be an associated risk of side effects, 
including long term effects especially in those patients who are found to have a substantially 
longer survival (MGMT methylated patients) [19].
While our study is underpowered to statistically significantly suggest the possibility of 
individualized radiation fields based on biologic characteristics of the tumor, there are 
several other examples of biology affecting management in GBM. Multiple recent reports 
have suggested that the genetic subtype of GBM can affect the resectability of the tumor. 
Beiko et al performed IDH1 mutation sequencing and immunohistochemical analysis on 335 
patients with high-grade glioma [3]. 93 % of tumors with IDH1 mutations underwent 
complete resection versus 67 % of wild-type tumors (p <0.001). It is not farfetched to 
consider that in the near future, the aggressiveness of surgical resection, the size of 
radiotherapy margins, and the choice of chemotherapeutic agents will be dictated by 
individual tumor biology.
Use of genomic analysis of GBM has thus far identified the population of IDH mutants with 
a clear survival advantage over other subtypes [13]. Other clinical behaviors that may be 
affected include multifocality [20], the presence of satellite nodules [21], and the likelihood 
of pseudoprogression [22]. A major disadvantage of genomic analyses of GBM behavior is 
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that they are generally underpowered studies because of the expense and availability of fresh 
frozen tissue in a tumor bank. Large prospective trials of GBM, however, are now 
mandating the banking of tissue for genetic analysis. As such, it is likely that radiation 
planning and treatment will continue to evolve such that in time, patterns of progression may 
be predicted prior to designing a radiation field, allowing the radiation oncologist to 
personalize the prescribed CTV margin.
Conclusion
TCGA groups demonstrated no difference in survival or progression patterns. MGMT 
methylation predicted for a statistically significant decrease in in-field and marginal 
progression. There was a cohort of MGMT methylated patients with late marginal 
progression. Validations of these findings would have implications that could affect 
radiation field size.
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Kaplan–Meier plot of overall survival based on MGMT-methylation status
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a Kaplan–Meier plot of time to progression within the 60 Gy volume based on TCGA 
subtype. b Kaplan–Meier plot of time to progression within the 46 Gy volume based on 
TCGA subtype. (C classical, N neural, M mesenchymal, PN proneural)
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Table 1
Patient characteristics, genomics and methylation groupings
Demographics
 Age (mean, range) 58 (33–84)
Sex
  Male 21 (50 %)
  Female 21 (50 %)
Race
  White 36 (86 %)
  Other 6 (14 %)
RT Modality
  3D Conformal 19 (45 %)
  IMRT 23 (55 %)
Resection type
  Gross total resection (GTR) 21 (50 %)
  Sub-total resection (STR) 20 (48 %)
  Biopsy (bx) 1 (2 %)




Genomics and Methylation Groupings
 TCGA Groupings N (%)
  Mesenchymal 21 (51)
  Neural 7 (17)
  Proneural 7 (17)
  Classical 6 (15)
 MGMT Methylation
  MGMT-methylated 22 (54)
  MGMT Wild Type 19 (46)
 G-CIMP Methylation
  G-Cimp 5 (12)
  Non-G-Cimp 36 (88)
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Table 2






 Concurrent Temozolomide 20 (91) 18 (95)
 Adjuvant Temozolomide 14 (64) 14 (74)
Lines of Salvage Therapy
 0 14 (64) 9 (47)
 1 4 (18) 7 (37)
 2 3 (14) 2 (11)
 3 1 (5) 1 (5)
Progression volume
 High dose only 5 (23) 6 (32)
 Overlapping 6 (27) 10 (53)
 Low dose only 2 (9) 1 (5)
 Distant 3 (14) 2 (11)
 No progression 6 (27) 0 (0)
a
One patient did not have MGMT methylation status available
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